Immunophenotyping of bone marrow trephine biopsies

Research output: Contribution to journalArticle

Abstract

Monoclonal antibodies were first developed in the late 1970s. However, it was only in the mid 1980s that the first attempts were made to apply monoclonal antibodies and immunophenotyping to bone marrow trephine (BMT) biopsies. Initially this was performed on frozen sections which gave optimal antigen preservation. Problems occurred with poor tissue morphology as the frozen sections were not decalcified and poor cytological preservation. Subsequent developments to improve the quality of BMT immunophenotyping have been: 1. Increased number of antibodies to an increased range of antigens detectable. 2. Development of methods that can be applied to decalcified paraffin embedded BMT biopsies. 3. Antigen retrieval methods (e.g. enzyme, microwave, heat) to expose tissue antigens masked by the tissue preparation (i.e. fixation and decalcification). 4. Enhanced immunostaining methods (e.g. tyramide) to amplify the signal intensity. Alkaline phosphatase or horseradish peroxidase methods are now widely applied to fixed, decalcified paraffin embedded BMT specimens. The range of antigens that can be detected is similar to that for fresh cell samples (e.g. blood). Panels of antibodies are used for BMT biopsies as there are few antibodies that are truly cell type specific. Applications of monoclonal antibodies and immunophenotyping to BMT biopsies include: 1. Assessment of bone marrow cellularity. 2. Analysis of bone marrow when there is no aspirate available (dry tap). 3. To establish the extent and pattern of disease infiltration (e.g. focal disease). 4. Disease classification (e.g. leukaemia, lymphoma). 5. To monitor residual disease following therapy. 6. Detection of metastatic disease. The developments in immunophenotyping methods over the past 10 years have resulted in processed BMT biopsies being as suitable a tissue for immuno-staining as other material. A wide range of monoclonal antibodies can now be applied to BMT biopsies and there are numerous applications to BMT biopsies.

Original languageEnglish
Pages (from-to)55-56
Number of pages2
JournalAustralian Journal of Medical Science
Volume21
Issue number1
Publication statusPublished - 1 Dec 2000
Externally publishedYes

Fingerprint

Immunophenotyping
Biopsy
Bone
Bone Marrow
Antigens
Monoclonal Antibodies
Tissue
Frozen Sections
Paraffin
Antibodies
Horseradish Peroxidase
Microwaves
Infiltration
Alkaline Phosphatase
Lymphoma
Leukemia
Blood
Hot Temperature

Cite this

@article{77295bbbd9a44412a0da1ec5f48e4c68,
title = "Immunophenotyping of bone marrow trephine biopsies",
abstract = "Monoclonal antibodies were first developed in the late 1970s. However, it was only in the mid 1980s that the first attempts were made to apply monoclonal antibodies and immunophenotyping to bone marrow trephine (BMT) biopsies. Initially this was performed on frozen sections which gave optimal antigen preservation. Problems occurred with poor tissue morphology as the frozen sections were not decalcified and poor cytological preservation. Subsequent developments to improve the quality of BMT immunophenotyping have been: 1. Increased number of antibodies to an increased range of antigens detectable. 2. Development of methods that can be applied to decalcified paraffin embedded BMT biopsies. 3. Antigen retrieval methods (e.g. enzyme, microwave, heat) to expose tissue antigens masked by the tissue preparation (i.e. fixation and decalcification). 4. Enhanced immunostaining methods (e.g. tyramide) to amplify the signal intensity. Alkaline phosphatase or horseradish peroxidase methods are now widely applied to fixed, decalcified paraffin embedded BMT specimens. The range of antigens that can be detected is similar to that for fresh cell samples (e.g. blood). Panels of antibodies are used for BMT biopsies as there are few antibodies that are truly cell type specific. Applications of monoclonal antibodies and immunophenotyping to BMT biopsies include: 1. Assessment of bone marrow cellularity. 2. Analysis of bone marrow when there is no aspirate available (dry tap). 3. To establish the extent and pattern of disease infiltration (e.g. focal disease). 4. Disease classification (e.g. leukaemia, lymphoma). 5. To monitor residual disease following therapy. 6. Detection of metastatic disease. The developments in immunophenotyping methods over the past 10 years have resulted in processed BMT biopsies being as suitable a tissue for immuno-staining as other material. A wide range of monoclonal antibodies can now be applied to BMT biopsies and there are numerous applications to BMT biopsies.",
author = "Erber, {W. N.}",
year = "2000",
month = "12",
day = "1",
language = "English",
volume = "21",
pages = "55--56",
journal = "Australian Journal of Medical Science",
issn = "1038-1643",
publisher = "Australian Institute of Medical Scientists",
number = "1",

}

Immunophenotyping of bone marrow trephine biopsies. / Erber, W. N.

In: Australian Journal of Medical Science, Vol. 21, No. 1, 01.12.2000, p. 55-56.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Immunophenotyping of bone marrow trephine biopsies

AU - Erber, W. N.

PY - 2000/12/1

Y1 - 2000/12/1

N2 - Monoclonal antibodies were first developed in the late 1970s. However, it was only in the mid 1980s that the first attempts were made to apply monoclonal antibodies and immunophenotyping to bone marrow trephine (BMT) biopsies. Initially this was performed on frozen sections which gave optimal antigen preservation. Problems occurred with poor tissue morphology as the frozen sections were not decalcified and poor cytological preservation. Subsequent developments to improve the quality of BMT immunophenotyping have been: 1. Increased number of antibodies to an increased range of antigens detectable. 2. Development of methods that can be applied to decalcified paraffin embedded BMT biopsies. 3. Antigen retrieval methods (e.g. enzyme, microwave, heat) to expose tissue antigens masked by the tissue preparation (i.e. fixation and decalcification). 4. Enhanced immunostaining methods (e.g. tyramide) to amplify the signal intensity. Alkaline phosphatase or horseradish peroxidase methods are now widely applied to fixed, decalcified paraffin embedded BMT specimens. The range of antigens that can be detected is similar to that for fresh cell samples (e.g. blood). Panels of antibodies are used for BMT biopsies as there are few antibodies that are truly cell type specific. Applications of monoclonal antibodies and immunophenotyping to BMT biopsies include: 1. Assessment of bone marrow cellularity. 2. Analysis of bone marrow when there is no aspirate available (dry tap). 3. To establish the extent and pattern of disease infiltration (e.g. focal disease). 4. Disease classification (e.g. leukaemia, lymphoma). 5. To monitor residual disease following therapy. 6. Detection of metastatic disease. The developments in immunophenotyping methods over the past 10 years have resulted in processed BMT biopsies being as suitable a tissue for immuno-staining as other material. A wide range of monoclonal antibodies can now be applied to BMT biopsies and there are numerous applications to BMT biopsies.

AB - Monoclonal antibodies were first developed in the late 1970s. However, it was only in the mid 1980s that the first attempts were made to apply monoclonal antibodies and immunophenotyping to bone marrow trephine (BMT) biopsies. Initially this was performed on frozen sections which gave optimal antigen preservation. Problems occurred with poor tissue morphology as the frozen sections were not decalcified and poor cytological preservation. Subsequent developments to improve the quality of BMT immunophenotyping have been: 1. Increased number of antibodies to an increased range of antigens detectable. 2. Development of methods that can be applied to decalcified paraffin embedded BMT biopsies. 3. Antigen retrieval methods (e.g. enzyme, microwave, heat) to expose tissue antigens masked by the tissue preparation (i.e. fixation and decalcification). 4. Enhanced immunostaining methods (e.g. tyramide) to amplify the signal intensity. Alkaline phosphatase or horseradish peroxidase methods are now widely applied to fixed, decalcified paraffin embedded BMT specimens. The range of antigens that can be detected is similar to that for fresh cell samples (e.g. blood). Panels of antibodies are used for BMT biopsies as there are few antibodies that are truly cell type specific. Applications of monoclonal antibodies and immunophenotyping to BMT biopsies include: 1. Assessment of bone marrow cellularity. 2. Analysis of bone marrow when there is no aspirate available (dry tap). 3. To establish the extent and pattern of disease infiltration (e.g. focal disease). 4. Disease classification (e.g. leukaemia, lymphoma). 5. To monitor residual disease following therapy. 6. Detection of metastatic disease. The developments in immunophenotyping methods over the past 10 years have resulted in processed BMT biopsies being as suitable a tissue for immuno-staining as other material. A wide range of monoclonal antibodies can now be applied to BMT biopsies and there are numerous applications to BMT biopsies.

UR - http://www.scopus.com/inward/record.url?scp=33750269019&partnerID=8YFLogxK

M3 - Article

VL - 21

SP - 55

EP - 56

JO - Australian Journal of Medical Science

JF - Australian Journal of Medical Science

SN - 1038-1643

IS - 1

ER -